Download Files:
Products Details
Product Description
– HAT-SIL-TG-1&AT is a Janus tyrosine kinase (JAK) inhibitor with antitumor effects. HAT-SIL-TG-1&AT is the hypoxia-activated prodrug, witch inhibits JAK-STAT signaling in tumor tissue. And HAT-SIL-TG-1&AT inhibits HEL cells proliferation and downregulated phosphorylated STAT3/5 under hypoxic conditions[1].
Web ID
– HY-149257
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C60H69N17O11S
References
– [1]Chen X, et al. A JAK tyrosine kinase and pseudokinase Co-inhibition strategy combines enhanced potency and on-demand activation. Eur J Med Chem. 2023 Mar 15;250:115198.
Molecular Weight
– 1236.36
SMILES
– CC1=CC(COC(N2C=C(C(C3=NC4=C(N3)C=CC(CN5CCOCC5)=C4)=N2)NC(NC6CC6)=O)=O)=C(C(COC(N7CCN(CC7)C8=CC=C(C=C8)NC9=NC=C(C(NC%10=CC(S(=O)(NC(C)(C)C)=O)=CC=C%10)=N9)C)=O)=C1)OCC%11=CN=C(N%11C)[N+]([O-])=O
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– JAK;STAT
Isoform
– STAT3;STAT5
Pathway
– Epigenetics;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK;Stem Cell/Wnt
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
